FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2537566568> ?p ?o ?g. }

• W2537566568 abstract "Abstract Introduction: XPO1 (CRM1, Exportin 1) is the sole transporter of many tumor suppressor proteins (including MYC, BCL2, BCL6, BTK, IkB) and is elevated in non-Hodgkin Lymphoma. Selinexor (Sel, KPT-330) is an oral covalent inhibitor of XPO1, the first clinical molecule of the Selective Inhibitors of Nuclear Export drug class. The phase I clinical trial of Sel in hematologic malignancies showed promising early single-agent efficacy with modest toxicity in relapsed Diffuse Large B-cell Lymphoma (DLBCL, Gutierrez et al, ASCO 2014). DLBCL, the most common lymphoid malignancy, is currently cured in only 10% of relapsed patients, and consists of 2 subtypes based on putative cell of origin (COO): activated B-cell (ABC) and germinal center B-cell (GCB). We performed preclinical studies of Sel, modeling its single-agent efficacy in frontline and relapsed DLBCL and its potential synergy with other clinically relevant therapeutics. Long-term follow-up data on patients(pts) treated with Radiolabeled antibody 90-yttrium-Ibritumomab Tiuxetan (RIT) are necessary to define the role of RIT-therapy (RIT-t) in current clinical practice. There are few reports about the use of RIT outside clinical trials. Outcome and toxicity of radioimmunotherapy remain a matter of concern. Incidence of MDS/AML reported after RIT-t as consolidation in front line varies from 3 to 4.3% (Czuczman et al, JCO 2007; Morschhauser et al, JCO 2012). A recent study with RIT and autologous stem cell transplantation (ASCT) as front line therapy in mantle cell lymphoma reported 20% incidence of secondary malignancies, (Arranz et al, Haemat 2013). So the aim of this study was to analyze the outcome of pts treated with RIT-t in clinical practice and to assess the incidence of secondary neoplasia particularly MDS/AML. We included in this retrospective analysis all pts with Diffuse B Large Cell Lymphoma (DBLCL), Follicular Lymphoma (FL) and Marginal Zone lymphoma (MZL), treated with RIT-t over the last decade at our Institution. We adopted the standard RIT therapeutic regimen: infusion of 250 mg/m2 rituximab on day 1, a second 250 mg/m2 dose on day 7, followed by dose of RIT (0.4 mCi/kg), administered 4 h following rituximab infusion. Response assessment was made as recommended by International Workshop criteria. Survival analysis was performed with Kaplan-Meier method and univariate analysis with Log-Rank test with a significance at 0.05. Between March 2006 and January 2014 61 pts underwent RIT-t, of these 57 had complete data and were considered for analysis. There were 16 DBLCL, 29 Follicular Lymphoma and 12 MZL. Twentythree were male, 34 female. Median age at diagnosis was 62 years(yrs) (range 36; 79), 66yrs (range 39;79) at RIT-t. Thirteen pts (all DBLCL) received RIT-t as front line consolidation. Forty-four pts (3 DBLCL, 12 MZL, 29 FL) underwent RIT-t after ≥1 therapy line: one prior line was received by 15pts, 2 by 19, 3 by 8 and 4 by 2. Before RIT-t 24pts were in relapse (2DBLCL, 2MZL, 20FL), 9 were refractory (2 MZL, 7 FL), 7 in partial response (1 DBLCL, 5 MZL, 1FL) while 4 were in complete remission (2 MZL, 2FL). Disclosures No relevant conflicts of interest to declare." @default.
• W2537566568 created "2016-10-28" @default.
• W2537566568 creator A5016966610 @default.
• W2537566568 creator A5022734562 @default.
• W2537566568 creator A5030504855 @default.
• W2537566568 creator A5034123305 @default.
• W2537566568 creator A5040899311 @default.
• W2537566568 creator A5050369634 @default.
• W2537566568 creator A5062581616 @default.
• W2537566568 creator A5073599258 @default.
• W2537566568 creator A5076236981 @default.
• W2537566568 creator A5089268268 @default.
• W2537566568 date "2014-12-06" @default.
• W2537566568 modified "2023-09-27" @default.
• W2537566568 title "90Yttrium-Ibritumomab Tiuxetan for Non-Hodgkin Lymphoma: Results after a Median Follow-up of 5 Years in a Single Institution" @default.
• W2537566568 doi "https://doi.org/10.1182/blood.v124.21.4455.4455" @default.
• W2537566568 hasPublicationYear "2014" @default.
• W2537566568 type Work @default.
• W2537566568 sameAs 2537566568 @default.
• W2537566568 citedByCount "0" @default.
• W2537566568 crossrefType "journal-article" @default.
• W2537566568 hasAuthorship W2537566568A5016966610 @default.
• W2537566568 hasAuthorship W2537566568A5022734562 @default.
• W2537566568 hasAuthorship W2537566568A5030504855 @default.
• W2537566568 hasAuthorship W2537566568A5034123305 @default.
• W2537566568 hasAuthorship W2537566568A5040899311 @default.
• W2537566568 hasAuthorship W2537566568A5050369634 @default.
• W2537566568 hasAuthorship W2537566568A5062581616 @default.
• W2537566568 hasAuthorship W2537566568A5073599258 @default.
• W2537566568 hasAuthorship W2537566568A5076236981 @default.
• W2537566568 hasAuthorship W2537566568A5089268268 @default.
• W2537566568 hasConcept C126322002 @default.
• W2537566568 hasConcept C143998085 @default.
• W2537566568 hasConcept C159654299 @default.
• W2537566568 hasConcept C203014093 @default.
• W2537566568 hasConcept C2776146153 @default.
• W2537566568 hasConcept C2777525834 @default.
• W2537566568 hasConcept C2778515704 @default.
• W2537566568 hasConcept C2778559949 @default.
• W2537566568 hasConcept C2779338263 @default.
• W2537566568 hasConcept C2911091166 @default.
• W2537566568 hasConcept C542903549 @default.
• W2537566568 hasConcept C71924100 @default.
• W2537566568 hasConceptScore W2537566568C126322002 @default.
• W2537566568 hasConceptScore W2537566568C143998085 @default.
• W2537566568 hasConceptScore W2537566568C159654299 @default.
• W2537566568 hasConceptScore W2537566568C203014093 @default.
• W2537566568 hasConceptScore W2537566568C2776146153 @default.
• W2537566568 hasConceptScore W2537566568C2777525834 @default.
• W2537566568 hasConceptScore W2537566568C2778515704 @default.
• W2537566568 hasConceptScore W2537566568C2778559949 @default.
• W2537566568 hasConceptScore W2537566568C2779338263 @default.
• W2537566568 hasConceptScore W2537566568C2911091166 @default.
• W2537566568 hasConceptScore W2537566568C542903549 @default.
• W2537566568 hasConceptScore W2537566568C71924100 @default.
• W2537566568 hasLocation W25375665681 @default.
• W2537566568 hasOpenAccess W2537566568 @default.
• W2537566568 hasPrimaryLocation W25375665681 @default.
• W2537566568 hasRelatedWork W1969132917 @default.
• W2537566568 hasRelatedWork W1980880418 @default.
• W2537566568 hasRelatedWork W1999488095 @default.
• W2537566568 hasRelatedWork W2100474253 @default.
• W2537566568 hasRelatedWork W2227791055 @default.
• W2537566568 hasRelatedWork W2507412273 @default.
• W2537566568 hasRelatedWork W2551597720 @default.
• W2537566568 hasRelatedWork W2554708763 @default.
• W2537566568 hasRelatedWork W2558956640 @default.
• W2537566568 hasRelatedWork W2563084408 @default.
• W2537566568 hasRelatedWork W2583616819 @default.
• W2537566568 hasRelatedWork W2586040923 @default.
• W2537566568 hasRelatedWork W2588047585 @default.
• W2537566568 hasRelatedWork W2588576916 @default.
• W2537566568 hasRelatedWork W2588670352 @default.
• W2537566568 hasRelatedWork W2591057097 @default.
• W2537566568 hasRelatedWork W2592062362 @default.
• W2537566568 hasRelatedWork W2594383555 @default.
• W2537566568 hasRelatedWork W2603119644 @default.
• W2537566568 hasRelatedWork W1996506292 @default.
• W2537566568 isParatext "false" @default.
• W2537566568 isRetracted "false" @default.
• W2537566568 magId "2537566568" @default.
• W2537566568 workType "article" @default.